[INTERVIEW] Breaking Barriers in Cancer Treatment: Race Oncology Pioneers a New Era with Bisantrene, page-189

The two trials starting later this year will both be funded come next month.

No cap raise needed for at least two years, and that's only IF the piggyback options for P2 aren't exercised.

Let me put it this way for you, these are the two scenarios for the 2026 trials:

1: If the two trials this year have good interim results, people won't think twice about exercising at $1.25 - the SP is above that right now, before any trails have even begun.

2: If the two trails this year have poor interim results, a capital raise will not be necessary anyway, because the drug doesn't work.



Yes, RC220 is technically viewed as a new drug, despite many, many times the company reiterating that it will likely perform just as well as the previously approved RC110. So consequently, these trials are Phase 1, but have a look at the data being collected from the trial instead of just thinking of it is a typical "Phase 1" "Phase 2"

RC220 is almost literally RC110, it is just reformulated to increase the ease, comfort and range of use - and to massively extend the patent life for RAC.

The latest AGM or the investor presentation for the new strategy explains all of this and more in detail, if you are interested, please check that out and come back with any questions. If you are just here because of Mason posting in the IMU threads, please be happy with the stirring you have done so far and give it a rest.